Researchers at the University of Michigan helped develop a newly approved therapy for a hard-to-treat form of acute myeloid leukemia, marking a major step forward for patients with NPM1-mutant disease. Their work with industry partners moved a scientific discovery from the lab into a real treatment now available to those in need. Ongoing studies are exploring how the therapy may be used more broadly in the future.
